Kristy S Pahl1, Arkopal Choudhury2, Katie Wusik3, Adrienne Hammill4, Andrew White5, Katharine Henderson6, Jeffrey Pollak6, Raj S Kasthuri7. 1. Division of Pediatric Hematology and Oncology, University of North Carolina School of Medicine, Chapel Hill, NC. 2. Department of Biostatistics, University of North Carolina-Chapel Hill, Chapel Hill, NC. 3. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH; Cancer and Blood Diseases Institute, Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 5. Division of Pediatric Rheumatology, Washington University, St Louis, MO. 6. Department of Interventional Radiology, Yale University School of Medicine, New Haven, CT. 7. Division of Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.
Abstract
OBJECTIVE: To evaluate the accuracy of the clinical Curaçao criteria in the diagnosis of hereditary hemorrhagic telangiectasia (HHT) in children and adolescents. STUDY DESIGN: This was a retrospective, multicenter chart review of 673 patients evaluated between 2002 and 2016; 290 were eligible for the study. Genetic testing for a pathogenic mutation was considered the gold standard against which the clinical Curaçao criteria were compared. Patients were divided into 4 age categories: 0-5, 6-10, 11-15, and 16-21-years. Sensitivity and specificity were calculated for each age group, and for the overall population. RESULTS: Overall the Curaçao criteria had a sensitivity of 68% (95% CI 60%-76%) and a specificity of 98% (95% CI 91%-100%). Sensitivity was lowest in the 0- to 5-year group, and increased with advancing age. The Curaçao criteria had the highest sensitivity in the 16- to 21-year-olds. Specificity was 100% in all age groups except for the 11- to 15-year-olds. CONCLUSIONS: This study evaluated the use of the Curaçao criteria for the diagnosis of HHT in the pediatric population with a family history of HHT. In those between the age of 0 and 21 years who meet 1 criterion (unlikely HHT) or 2 criteria (possible HHT), genetic testing is preferred for diagnosis. The Curaçao criteria appear to reliably diagnose HHT in children and adolescents who meet 3 or 4 criteria (definite HHT).
OBJECTIVE: To evaluate the accuracy of the clinical Curaçao criteria in the diagnosis of hereditary hemorrhagic telangiectasia (HHT) in children and adolescents. STUDY DESIGN: This was a retrospective, multicenter chart review of 673 patients evaluated between 2002 and 2016; 290 were eligible for the study. Genetic testing for a pathogenic mutation was considered the gold standard against which the clinical Curaçao criteria were compared. Patients were divided into 4 age categories: 0-5, 6-10, 11-15, and 16-21-years. Sensitivity and specificity were calculated for each age group, and for the overall population. RESULTS: Overall the Curaçao criteria had a sensitivity of 68% (95% CI 60%-76%) and a specificity of 98% (95% CI 91%-100%). Sensitivity was lowest in the 0- to 5-year group, and increased with advancing age. The Curaçao criteria had the highest sensitivity in the 16- to 21-year-olds. Specificity was 100% in all age groups except for the 11- to 15-year-olds. CONCLUSIONS: This study evaluated the use of the Curaçao criteria for the diagnosis of HHT in the pediatric population with a family history of HHT. In those between the age of 0 and 21 years who meet 1 criterion (unlikely HHT) or 2 criteria (possible HHT), genetic testing is preferred for diagnosis. The Curaçao criteria appear to reliably diagnose HHT in children and adolescents who meet 3 or 4 criteria (definite HHT).
Authors: Rosario Sánchez-Martínez; Adriana Iriarte; José María Mora-Luján; José Luis Patier; Daniel López-Wolf; Ana Ojeda; Miguel Angel Torralba; María Coloma Juyol; Ricardo Gil; Sol Añón; Joel Salazar-Mendiguchía; Antoni Riera-Mestre Journal: Orphanet J Rare Dis Date: 2020-06-05 Impact factor: 4.123
Authors: Hamza Yunus; Said Amin; Furqan Ul Haq; Waqar Ali; Tanveer Hamid; Wajid Ali; Basharat Ullah; Payal Bai Journal: Front Med (Lausanne) Date: 2022-10-03
Authors: Els M de Gussem; Steven Kroon; Anna E Hosman; Johannes C Kelder; Martijn C Post; Repke J Snijder; Johannes J Mager Journal: J Clin Med Date: 2020-11-06 Impact factor: 4.241
Authors: Alexandra Kilian; Giuseppe A Latino; Andrew J White; Dewi Clark; Murali M Chakinala; Felix Ratjen; Jamie McDonald; Kevin Whitehead; James R Gossage; Doris Lin; Katharine Henderson; Jeffrey Pollak; Justin P McWilliams; Helen Kim; Michael T Lawton; Marie E Faughnan Journal: J Clin Med Date: 2020-08-22 Impact factor: 4.241